|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US7097840B2
(en)
*
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
AU2002311919B8
(en)
|
2001-05-11 |
2007-03-22 |
Ludwig Institute For Cancer Research Ltd |
Specific binding proteins and uses thereof
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
EP1506286B1
(en)
*
|
2002-05-24 |
2014-03-19 |
Merck Sharp & Dohme Corp. |
Neutralizing human anti-igfr antibody
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
*
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
CA2556752C
(en)
*
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
NZ579482A
(en)
*
|
2004-06-01 |
2011-02-25 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
CA2486285C
(en)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
JP4993645B2
(ja)
|
2004-12-01 |
2012-08-08 |
ジェネンテック， インコーポレイテッド |
抗体薬剤結合体および方法
|
|
ES2503719T3
(es)
*
|
2005-02-11 |
2014-10-07 |
Immunogen, Inc. |
Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
JP4875064B2
(ja)
*
|
2005-04-15 |
2012-02-15 |
シェーリング コーポレイション |
癌を処置または予防するための方法および組成物
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
CA3000520C
(en)
|
2005-08-24 |
2023-04-04 |
Immunogen, Inc. |
Process for preparing antibody maytansinoid conjugates
|
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
|
EP1942944A2
(en)
*
|
2005-10-31 |
2008-07-16 |
Genentech, Inc. |
Macrocyclic depsipeptide antibody-drug conjugates and methods
|
|
SI1976884T1
(sl)
|
2006-01-20 |
2013-04-30 |
Genetech, Inc. |
Anti-efrinB2 protitelesa in postopki uporabe le teh
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
EP2032606B1
(en)
|
2006-05-30 |
2013-11-27 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
BRPI0717638A2
(pt)
|
2006-10-27 |
2013-11-12 |
Genentech Inc |
Anticorpors e imunoconjugados e usos para os mesmos
|
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
CA2680854C
(en)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
CN101679974B
(zh)
|
2007-03-27 |
2015-09-30 |
航道生物技术有限责任公司 |
包含抗体替代轻链序列的构建体和文库
|
|
US20090011060A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Peter Koepke |
Campsiandra angustifolia extract and methods of extracting and using such extract
|
|
PE20090943A1
(es)
*
|
2007-07-16 |
2009-08-05 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados
|
|
EP2176295B1
(en)
*
|
2007-07-16 |
2014-11-19 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
|
PL2187965T3
(pl)
|
2007-08-17 |
2020-05-18 |
Purdue Research Foundation |
Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
|
|
US7879369B2
(en)
|
2007-09-18 |
2011-02-01 |
Selvamedica, Llc |
Combretum laurifolium Mart. extract and methods of extracting and using such extract
|
|
KR101607346B1
(ko)
|
2008-01-31 |
2016-03-29 |
제넨테크, 인크. |
항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
|
|
DK2644194T3
(en)
|
2008-03-18 |
2017-07-03 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
WO2009134870A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Immunogen, Inc. |
Potent cell-binding agent drug conjugates
|
|
SG189817A1
(en)
*
|
2008-04-30 |
2013-05-31 |
Immunogen Inc |
Potent conjugates and hydrophilic linkers
|
|
NZ610239A
(en)
|
2008-04-30 |
2014-11-28 |
Immunogen Inc |
Cross-linkers and their uses
|
|
US20100092495A1
(en)
*
|
2008-04-30 |
2010-04-15 |
Immunogen Inc. |
Potent cell-binding agent drug conjugates
|
|
ES2442024T3
(es)
|
2008-07-15 |
2014-02-07 |
Academia Sinica |
Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
|
|
RU2683325C2
(ru)
|
2009-02-05 |
2019-03-28 |
Иммьюноджен, Инк. |
Новые производные бензодиазепина
|
|
MA33208B1
(fr)
|
2009-03-25 |
2012-04-02 |
Genentech Inc |
Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
|
|
RU2587621C2
(ru)
|
2009-04-01 |
2016-06-20 |
Дженентек, Инк. |
АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
EP2424875B1
(en)
|
2009-04-29 |
2016-01-06 |
Bio-Rad Laboratories, Inc. |
Purification of immunoconjugates
|
|
CA2761681A1
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
SG10201810743WA
(en)
|
2009-06-03 |
2018-12-28 |
Immunogen Inc |
Conjugation methods
|
|
MX2011012665A
(es)
|
2009-06-04 |
2012-03-07 |
Novartis Ag |
Metodos para identificacion de sitios para conjugacion de igg.
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
JP2013504585A
(ja)
*
|
2009-09-09 |
2013-02-07 |
セントローズ， エルエルシー |
細胞外標的化薬物複合体
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
EP2478013B1
(en)
|
2009-09-16 |
2018-10-24 |
F.Hoffmann-La Roche Ag |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
CN102596922A
(zh)
*
|
2009-10-06 |
2012-07-18 |
免疫基因公司 |
有效的缀合物和亲水性连接体
|
|
JP5697677B2
(ja)
*
|
2009-10-26 |
2015-04-08 |
ネステク ソシエテ アノニム |
抗ｔｎｆ薬及び自己抗体の検出用アッセイ
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
CN102770456B
(zh)
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
|
US20110165155A1
(en)
*
|
2009-12-04 |
2011-07-07 |
Genentech, Inc. |
Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
|
|
EP2516465B1
(en)
|
2009-12-23 |
2016-05-18 |
F.Hoffmann-La Roche Ag |
Anti-bv8 antibodies and uses thereof
|
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Ｃｄ２０ 항체 및 이의 용도
|
|
MA34057B1
(fr)
|
2010-02-23 |
2013-03-05 |
Genentech Inc |
Compositions et methodes pour le diagnostic et le traitement d'une tumeur
|
|
TWI622402B
(zh)
|
2010-02-24 |
2018-05-01 |
免疫遺傳股份有限公司 |
葉酸受體１抗體類和免疫共軛物類及彼等之用途
|
|
US9951324B2
(en)
|
2010-02-25 |
2018-04-24 |
Purdue Research Foundation |
PSMA binding ligand-linker conjugates and methods for using
|
|
SG10201501803YA
(en)
|
2010-03-12 |
2015-05-28 |
Immunogen Inc |
Cd37-binding molecules and immunoconjugates thereof
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
KR101860963B1
(ko)
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
|
NZ701208A
(en)
|
2010-06-03 |
2016-05-27 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
|
|
CA2799540A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
EA201390472A1
(ru)
|
2010-10-29 |
2014-02-28 |
Иммьюноджен, Инк. |
Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
|
|
EA201390575A1
(ru)
*
|
2010-10-29 |
2014-01-30 |
Иммьюноджен, Инк. |
Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
|
|
US20120121615A1
(en)
|
2010-11-17 |
2012-05-17 |
Flygare John A |
Alaninyl maytansinol antibody conjugates
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
ES2860748T3
(es)
|
2011-01-24 |
2021-10-05 |
Gilead Sciences Inc |
Anticuerpos selectivos para células que presentan EGFR con alta densidad
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
RU2018108836A
(ru)
|
2011-02-04 |
2019-03-14 |
Дженентек, Инк. |
ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
|
JP5826863B2
(ja)
|
2011-02-15 |
2015-12-02 |
イミュノジェン・インコーポレーテッド |
細胞傷害性ベンゾジアゼピン誘導体
|
|
AU2012236403B2
(en)
*
|
2011-03-29 |
2016-08-04 |
Immunogen, Inc. |
Process for manufacturing conjugates of improved homogeneity
|
|
ME03353B
(me)
|
2011-03-29 |
2019-10-20 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
MY171008A
(en)
|
2011-03-29 |
2019-09-23 |
Immunogen Inc |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
AU2012236210B2
(en)
|
2011-04-01 |
2016-02-04 |
Immunogen, Inc. |
CD37-binding molecules and immunoconjugates thereof
|
|
BR112013025415B1
(pt)
|
2011-04-01 |
2021-03-16 |
Immunogen, Inc |
uso de um imunoconjugado antirreceptor de folato 1 (folr1)
|
|
SG194735A1
(en)
|
2011-05-09 |
2013-12-30 |
Univ Virginia Patent Found |
Compositions and methods for treating cancer
|
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
JP6209159B2
(ja)
|
2011-06-21 |
2017-10-04 |
イミュノジェン・インコーポレーテッド |
ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
|
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
|
MX353958B
(es)
|
2011-09-22 |
2018-02-07 |
Amgen Inc |
Proteinas de union al antigeno cd27l.
|
|
WO2013049521A2
(en)
*
|
2011-09-29 |
2013-04-04 |
Virginia Commonwealth University |
Light-enabled drug delivery
|
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
|
PE20141937A1
(es)
|
2011-11-16 |
2014-12-18 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
|
|
CA2856411A1
(en)
|
2011-11-21 |
2013-05-30 |
Immunogen, Inc. |
Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
|
|
KR20140100571A
(ko)
|
2011-12-08 |
2014-08-14 |
바이오테스트 아게 |
Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
EP2793947B1
(en)
*
|
2011-12-23 |
2021-02-03 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
|
CA2861124A1
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
CA2869704A1
(en)
|
2012-04-04 |
2013-10-10 |
Perseus Proteomics Inc. |
Drug conjugate comprising anti-cdh3 (pcadherin) antibody
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
CN110078827A
(zh)
|
2012-04-27 |
2019-08-02 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
US9056910B2
(en)
|
2012-05-01 |
2015-06-16 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
CN104640572B
(zh)
|
2012-05-15 |
2018-04-27 |
索伦托医疗有限公司 |
药物偶联物，偶联方法，及其用途
|
|
WO2013173337A2
(en)
|
2012-05-15 |
2013-11-21 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
CN104540519B
(zh)
|
2012-05-21 |
2018-06-01 |
基因泰克公司 |
抗Ly6E抗体和免疫缀合物及使用方法
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
JP2015528818A
(ja)
|
2012-08-02 |
2015-10-01 |
ジェネンテック， インコーポレイテッド |
抗ｅｔｂｒ抗体およびイムノコンジュゲート
|
|
CA2879670A1
(en)
|
2012-08-02 |
2014-02-06 |
Genentech, Inc. |
Anti-etbr antibodies and immunoconjugates
|
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
LT3486248T
(lt)
|
2012-09-26 |
2021-08-25 |
Immunogen, Inc. |
Patobulinti maitansinolio acilinimo būdai
|
|
RU2661083C2
(ru)
|
2012-10-04 |
2018-07-11 |
Иммуноджен, Инк. |
Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
|
|
EA201590783A1
(ru)
|
2012-11-15 |
2015-11-30 |
Эндосайт, Инк. |
Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
CN104688740A
(zh)
*
|
2012-12-21 |
2015-06-10 |
百奥泰生物科技(广州)有限公司 |
类美登素衍生物及其制备方法和用途
|
|
CN103333246B
(zh)
*
|
2012-12-21 |
2015-09-16 |
百奥泰生物科技(广州)有限公司 |
一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
|
|
EP3566750A3
(en)
|
2013-02-28 |
2020-04-08 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
JP6423804B2
(ja)
|
2013-02-28 |
2018-11-14 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤を含む複合体
|
|
US9498532B2
(en)
*
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9415118B2
(en)
|
2013-03-13 |
2016-08-16 |
Novartis Ag |
Antibody drug conjugates
|
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及びイムノコンジュゲート
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
ES2701051T3
(es)
|
2013-03-15 |
2019-02-20 |
Novartis Ag |
Conjugados de anticuerpo-fármaco
|
|
JP6847388B2
(ja)
|
2013-03-15 |
2021-03-31 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
生物活性分子、そのコンジュゲート、及び治療用途
|
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
|
JP6574754B2
(ja)
|
2013-03-19 |
2019-09-11 |
ベイジン シェノゲン ファーマ グループ リミテッド |
エストロゲン受容体関連疾患を処置するための抗体及び方法
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
GB201309807D0
(en)
|
2013-05-31 |
2013-07-17 |
Pharma Mar Sau |
Antibody drug conjugates
|
|
KR20160018579A
(ko)
*
|
2013-06-04 |
2016-02-17 |
싸이톰스 테라퓨틱스, 인크. |
활성화가능 항체를 접합하기 위한 조성물 및 방법
|
|
US10071170B2
(en)
|
2013-06-24 |
2018-09-11 |
Ablbio |
Antibody-drug conjugate having improved stability and use thereof
|
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
EP3013347B1
(en)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
ES2809501T3
(es)
|
2013-07-05 |
2021-03-04 |
Formation Biologics Inc |
Conjugados de anticuerpo de EGFR
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
RU2560699C2
(ru)
*
|
2013-08-02 |
2015-08-20 |
федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) |
Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител
|
|
TWI641620B
(zh)
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
US9545451B2
(en)
|
2013-08-21 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
|
|
BR112016004023A2
(pt)
|
2013-08-26 |
2022-11-16 |
Regeneron Pharma |
Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
|
|
WO2015035108A1
(en)
|
2013-09-05 |
2015-03-12 |
The Jackson Laboratory |
Compositions for rna-chromatin interaction analysis and uses thereof
|
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
|
|
JP2016537399A
(ja)
|
2013-09-17 |
2016-12-01 |
ジェネンテック， インコーポレイテッド |
抗ｌｇｒ５抗体を使用する方法
|
|
PL3055332T3
(pl)
|
2013-10-08 |
2020-02-28 |
Immunogen, Inc. |
Schematy dawkowania immunokoniugatu anty-FOLR1
|
|
KR102087850B1
(ko)
|
2013-10-11 |
2020-03-12 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-고분자-약물 접합체
|
|
ES2754397T3
(es)
|
2013-10-11 |
2020-04-17 |
Asana Biosciences Llc |
Conjugados de proteína-polímero-fármaco
|
|
AU2014337317A1
(en)
|
2013-10-15 |
2016-09-15 |
Sorrento Therapeutics Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
|
NZ758049A
(en)
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
|
EP3456700A1
(en)
|
2013-10-18 |
2019-03-20 |
Deutsches Krebsforschungszentrum |
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
|
|
WO2015061209A1
(en)
|
2013-10-21 |
2015-04-30 |
Genentech, Inc. |
ANTI-Ly6E ANTIBODIES AND METHODS OF USE
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
JP2016538283A
(ja)
|
2013-11-13 |
2016-12-08 |
ザイムワークス，インコーポレイテッド |
Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
|
|
EP3533473A3
(en)
|
2013-11-14 |
2019-12-18 |
Endocyte, Inc. |
Compounds for positron emission tomography
|
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
TWI541022B
(zh)
|
2013-12-18 |
2016-07-11 |
應克隆公司 |
針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
|
|
SI3082878T1
(sl)
|
2013-12-19 |
2023-01-31 |
Seagen Inc. |
Metilen-karbamatni linkerji za uporabo s tarčnimi konjugati zdravila
|
|
US9943606B2
(en)
|
2014-01-15 |
2018-04-17 |
Rutgers, The State University Of New Jersey |
Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
|
|
US10214584B2
(en)
|
2014-01-15 |
2019-02-26 |
Order-Made Medical Research Inc. |
Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
|
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
SG11201605437YA
(en)
|
2014-01-27 |
2016-08-30 |
Pfizer |
Bifunctional cytotoxic agents
|
|
US10562977B2
(en)
|
2014-01-29 |
2020-02-18 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
|
|
KR20230088389A
(ko)
|
2014-02-11 |
2023-06-19 |
씨젠 인크. |
단백질의 선택적 환원
|
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
|
BR122021009041B1
(pt)
|
2014-05-06 |
2022-11-29 |
Genentech, Inc |
Métodos para a preparação de uma proteína heteromultimérica
|
|
JP7093612B2
(ja)
|
2014-05-27 |
2022-06-30 |
アカデミア シニカ |
Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
CA2950415A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
|
CN106661099A
(zh)
|
2014-05-27 |
2017-05-10 |
中央研究院 |
抗her2醣抗体及其用途
|
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
|
MX379365B
(es)
|
2014-06-30 |
2025-03-11 |
Tarveda Therapeutics Inc |
Conjugados y partículas direccionados y formulaciones de estos.
|
|
WO2016004043A1
(en)
*
|
2014-06-30 |
2016-01-07 |
Blend Therapeutics, Inc. |
Targeted conjugates and particles and formulations thereof
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
|
MA40513A
(fr)
|
2014-08-12 |
2017-06-21 |
Novartis Ag |
Conjugués médicament-anticorps anti-cdh6
|
|
SG11201701328XA
(en)
|
2014-09-02 |
2017-03-30 |
Immunogen Inc |
Methods for formulating antibody drug conjugate compositions
|
|
WO2016036804A1
(en)
|
2014-09-03 |
2016-03-10 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
|
AU2015311987B2
(en)
|
2014-09-03 |
2020-06-04 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
|
TWI745275B
(zh)
|
2014-09-08 |
2021-11-11 |
中央研究院 |
使用醣脂激活人類ｉＮＫＴ細胞
|
|
FI3900742T3
(fi)
|
2014-09-11 |
2024-08-16 |
Seagen Inc |
Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen
|
|
WO2016040724A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
|
HUE049175T2
(hu)
|
2014-09-23 |
2020-09-28 |
Hoffmann La Roche |
Eljárás anti-CD79b immunkonjugátumok alkalmazására
|
|
CA2961950A1
(en)
|
2014-09-28 |
2016-03-31 |
The Regents Of The University Of California |
Modulation of stimulatory and non-stimulatory myeloid cells
|
|
EP3218009B1
(en)
|
2014-10-14 |
2021-04-07 |
Polytherics Limited |
Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
|
|
TW201625692A
(zh)
|
2014-11-14 |
2016-07-16 |
諾華公司 |
抗體藥物結合物
|
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US10335495B2
(en)
|
2014-12-04 |
2019-07-02 |
Celgene Corporation |
Biomolecule conjugates
|
|
US10188759B2
(en)
|
2015-01-07 |
2019-01-29 |
Endocyte, Inc. |
Conjugates for imaging
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
新規なグリカンコンジュゲートおよびその使用方法
|
|
EP3250238B1
(en)
|
2015-01-28 |
2022-06-01 |
Sorrento Therapeutics, Inc. |
Antibody drug conjugates
|
|
US10870706B2
(en)
|
2015-03-20 |
2020-12-22 |
Pfizer Inc. |
Bifunctional cytotoxic agents containing the CTI pharmacophore
|
|
BR112017020149A8
(pt)
|
2015-03-27 |
2023-05-02 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
|
|
WO2016172485A2
(en)
|
2015-04-24 |
2016-10-27 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
|
TW201711702A
(zh)
|
2015-06-04 |
2017-04-01 |
應克隆公司 |
使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
|
|
EP3302561A4
(en)
|
2015-06-08 |
2019-02-06 |
Debiopharm International SA |
COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES
|
|
CN106243127B
(zh)
*
|
2015-06-09 |
2021-01-26 |
凯惠科技发展(上海)有限公司 |
抗体药物偶联物、中间体、制备方法、药物组合物及应用
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
SMT202000614T1
(it)
|
2015-06-29 |
2021-01-05 |
Immunogen Inc |
Coniugati di anticorpi ingegnerizzati con cisteina
|
|
WO2017003940A1
(en)
*
|
2015-06-30 |
2017-01-05 |
Tarveda Therapeutics, Inc. |
Targeted conjugates and particles and formulations thereof
|
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3325482B1
(en)
|
2015-07-21 |
2020-06-24 |
ImmunoGen, Inc. |
Methods of preparing cytotoxic benzodiazepine derivatives
|
|
US10509035B2
(en)
|
2015-08-07 |
2019-12-17 |
Gamamabs Pharma Sa |
Antibodies, antibody drug conjugates and methods of use
|
|
KR102766022B1
(ko)
|
2015-08-28 |
2025-02-10 |
데비오팜 인터네셔날 에스 에이 |
Cd37 의 검출을 위한 항체 및 검정
|
|
WO2017044530A1
(en)
*
|
2015-09-08 |
2017-03-16 |
Waters Technologies Corporation |
Multidimensional chromatoggraphy method for analysis of antibody-drug conjugates
|
|
CN116440279B
(zh)
|
2015-09-17 |
2026-02-24 |
伊缪诺金公司 |
包含抗folr1免疫缀合物的治疗组合
|
|
EP3359576B1
(en)
|
2015-10-08 |
2024-12-25 |
Zymeworks BC Inc. |
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
|
US11160871B2
(en)
|
2015-10-28 |
2021-11-02 |
Tarveda Therapeutics, Inc. |
SSTR-targeted conjugates and particles and formulations thereof
|
|
US20170189548A1
(en)
|
2015-11-25 |
2017-07-06 |
Immunogen, Inc. |
Pharmaceutical formulations and methods of use thereof
|
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
KR20180090290A
(ko)
|
2015-12-04 |
2018-08-10 |
시애틀 지네틱스, 인크. |
사차화 튜불리신 화합물들의 컨쥬게이트들
|
|
BR112018014759B1
(pt)
|
2016-01-25 |
2024-02-27 |
Regeneron Pharmaceuticals, Inc |
Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
|
|
US11129910B2
(en)
|
2016-02-04 |
2021-09-28 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
|
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
KR20180112060A
(ko)
|
2016-02-23 |
2018-10-11 |
타베다 세라퓨틱스, 인코포레이티드 |
Hsp90 표적화된 접합체 및 이의 입자 및 제형
|
|
EP3426693A4
(en)
|
2016-03-08 |
2019-11-13 |
Academia Sinica |
PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
|
|
CN109843919A
(zh)
|
2016-03-25 |
2019-06-04 |
西雅图基因公司 |
用于制备聚乙二醇化的药物-接头及其中间体的方法
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
CN109843327B
(zh)
|
2016-07-07 |
2022-05-13 |
小利兰·斯坦福大学托管委员会 |
抗体佐剂缀合物
|
|
TWI851531B
(zh)
|
2016-08-09 |
2024-08-11 |
美商思進公司 |
具有改善之生理化學性質之具自我穩定連接子之藥物結合物
|
|
US9950070B2
(en)
*
|
2016-08-16 |
2018-04-24 |
Korea University Research And Business Foundation |
HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
|
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
|
CA3039589A1
(en)
|
2016-10-18 |
2018-04-26 |
Seattle Genetics, Inc. |
Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
|
|
CN110177805B
(zh)
|
2016-10-19 |
2024-04-02 |
英温拉公司 |
抗体构建体
|
|
EP3535297B1
(en)
|
2016-11-02 |
2022-08-10 |
Debiopharm International, S.A. |
Methods for improving anti-cd37 immunoconjugate therapy
|
|
KR20220150408A
(ko)
|
2016-11-14 |
2022-11-10 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
WO2018098258A2
(en)
|
2016-11-23 |
2018-05-31 |
Immunogen, Inc. |
Selective sulfonation of benzodiazepine derivatives
|
|
EP3548514A1
(en)
|
2016-11-29 |
2019-10-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prlr positive breast cancer
|
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
|
EP3554544A4
(en)
|
2016-12-16 |
2020-07-29 |
Bluefin Biomedicine, Inc. |
ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
|
|
AU2017383142A1
(en)
|
2016-12-22 |
2019-07-04 |
Università Degli Studi Magna Graecia Catanzaro |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
|
|
PL3558391T3
(pl)
|
2016-12-23 |
2022-05-16 |
Immunogen, Inc. |
Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania
|
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
TWI781145B
(zh)
|
2017-02-28 |
2022-10-21 |
美商伊繆諾金公司 |
具有自分解肽連接子之類美登素衍生物及其結合物
|
|
KR102648564B1
(ko)
|
2017-03-24 |
2024-03-19 |
씨젠 인크. |
글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
WO2018195243A1
(en)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
|
KR102491180B1
(ko)
|
2017-04-27 |
2023-01-20 |
파르마 마르 에스.에이. |
항종양 화합물
|
|
CA3060206A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
US20180311375A1
(en)
*
|
2017-04-27 |
2018-11-01 |
Cadila Healthcare Limited |
Process of preparing antibody-drug conjugate
|
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
KR102611853B1
(ko)
|
2017-06-30 |
2023-12-08 |
자임워크스 비씨 인코포레이티드 |
안정화된 키메라 fabs
|
|
MX2020002241A
(es)
|
2017-08-28 |
2020-09-03 |
Angiex Inc |
Anticuerpos anti-tm4sf y métodos de uso de los mismos.
|
|
KR102820804B1
(ko)
|
2017-09-22 |
2025-06-16 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
CN119857155A
(zh)
|
2017-11-29 |
2025-04-22 |
海德堡医药研究有限责任公司 |
用于耗尽cd5+细胞的组合物和方法
|
|
US11793885B2
(en)
|
2017-12-28 |
2023-10-24 |
Immunogen, Inc. |
Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
|
|
WO2019150985A1
(ja)
*
|
2018-01-31 |
2019-08-08 |
国立大学法人東京大学 |
抗体薬物複合体及びそれを含む医薬組成物
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
CR20250325A
(es)
|
2018-04-13 |
2025-08-29 |
Genentech Inc |
Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
|
|
CN112368024A
(zh)
|
2018-04-17 |
2021-02-12 |
恩多塞特公司 |
治疗癌症的方法
|
|
US12144818B2
(en)
|
2018-05-30 |
2024-11-19 |
Debiopharm International, S.A. |
Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens
|
|
CN120795120A
(zh)
|
2018-06-05 |
2025-10-17 |
伦敦大学国王学院 |
向胃肠系统递送酬载的btnl3/8导引构建体
|
|
MX2020013466A
(es)
|
2018-06-26 |
2021-04-19 |
Immunogen Inc |
Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
|
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
CN112739339B
(zh)
|
2018-07-23 |
2024-12-27 |
海德堡医药研究有限责任公司 |
抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
|
|
CA3107383A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
|
SG11202100653YA
(en)
|
2018-07-25 |
2021-02-25 |
Daiichi Sankyo Co Ltd |
Effective method for manufacturing antibody-drug conjugate
|
|
WO2020063676A1
(zh)
|
2018-09-26 |
2020-04-02 |
江苏恒瑞医药股份有限公司 |
依喜替康类似物的配体-药物偶联物及其制备方法和应用
|
|
TWI897855B
(zh)
|
2018-10-26 |
2025-09-21 |
美商免疫遺傳股份有限公司 |
Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
|
|
MX2021010254A
(es)
|
2019-02-27 |
2021-09-21 |
Angiex Inc |
Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
|
|
WO2020190725A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
CN113795264A
(zh)
|
2019-03-19 |
2021-12-14 |
瓦尔希伯伦私人肿瘤研究基金会 |
采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
|
|
DK3941946T3
(da)
|
2019-03-20 |
2025-03-24 |
Univ California |
Claudin-6-antistoffer og lægemiddelkonjugater
|
|
US20220177583A1
(en)
|
2019-03-20 |
2022-06-09 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
|
CN113661172A
(zh)
|
2019-03-29 |
2021-11-16 |
伊缪诺金公司 |
用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
|
|
NZ781538A
(en)
|
2019-04-24 |
2025-12-19 |
Heidelberg Pharma Res Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
SG11202110922QA
(en)
|
2019-04-26 |
2021-10-28 |
Immunogen Inc |
Camptothecin derivatives
|
|
CN114096264B
(zh)
|
2019-05-20 |
2025-03-14 |
因多塞特股份有限公司 |
制备psma缀合物的方法
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
US11555019B2
(en)
|
2019-07-10 |
2023-01-17 |
Cybrexa 3, Inc. |
Peptide conjugates of microtubule-targeting agents as therapeutics
|
|
MX2022000449A
(es)
|
2019-07-10 |
2022-04-25 |
Cybrexa 2 Inc |
Conjugados peptídicos de citotoxinas como terapéuticos.
|
|
CN112125915A
(zh)
|
2019-09-18 |
2020-12-25 |
四川百利药业有限责任公司 |
一种喜树碱衍生物及其偶联物
|
|
JP7593323B2
(ja)
|
2019-09-26 |
2024-12-03 |
日油株式会社 |
ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール
|
|
US12435116B2
(en)
|
2019-10-16 |
2025-10-07 |
Clarence Hurt |
Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
|
|
EP4085077A4
(en)
|
2019-12-31 |
2024-01-17 |
Beijing QL Biopharmaceutical Co., Ltd. |
Fusion proteins of glp-1 and gdf15 and conjugates thereof
|
|
CN113728013B
(zh)
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
|
JP7821733B2
(ja)
|
2020-01-22 |
2026-02-27 |
上海森輝医薬有限公司 |
エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
|
|
WO2021173773A1
(en)
|
2020-02-25 |
2021-09-02 |
Mediboston, Inc. |
Camptothecin derivatives and conjugates thereof
|
|
CN111195353B
(zh)
*
|
2020-03-19 |
2023-06-23 |
烟台迈百瑞国际生物医药股份有限公司 |
一种美登素类抗体药物偶联物及其应用
|
|
CN115103858B
(zh)
|
2020-03-25 |
2025-07-15 |
江苏恒瑞医药股份有限公司 |
一种抗体药物偶联物的制备方法
|
|
BR112022019073A2
(pt)
|
2020-03-25 |
2022-11-08 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
|
|
AU2021251875A1
(en)
|
2020-04-10 |
2022-11-03 |
Seagen Inc. |
Charge variant linkers
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
US12521444B2
(en)
|
2021-02-25 |
2026-01-13 |
Fortvita Biologics Limited |
Anti-HER2 antibody-drug conjugates and uses thereof
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
CA3251592A1
(en)
|
2022-02-17 |
2025-07-09 |
Novelty Nobility Inc. |
ANTIBODY-DRUG CONJUGATE
|
|
EP4489859A1
(en)
|
2022-03-09 |
2025-01-15 |
Astrazeneca AB |
Binding molecules against fr alpha
|
|
KR20240162086A
(ko)
|
2022-03-11 |
2024-11-14 |
아스트라제네카 아베 |
항-FRα 항체-약물 접합체 치료법에 대한 점수 산정 방법
|
|
TW202412762A
(zh)
|
2022-07-27 |
2024-04-01 |
香港商祐方有限公司 |
奧瑞他汀衍生物及其結合物
|
|
EP4608429A1
(en)
|
2022-10-25 |
2025-09-03 |
Peptomyc, S.L. |
Combination therapy for the treatment of cancer
|
|
WO2024121632A1
(en)
|
2022-12-09 |
2024-06-13 |
Crispr Therapeutics Ag |
Use of anti-cd117 antibody drug conjugate (adc)
|
|
AU2024218327A1
(en)
|
2023-02-09 |
2025-09-25 |
Beone Medicines I Gmbh |
Self-stabilizing linker conjugates
|
|
CN120936382A
(zh)
|
2023-02-16 |
2025-11-11 |
阿斯利康(瑞典)有限公司 |
采用治疗性结合分子治疗癌症的组合疗法
|
|
CN120957753A
(zh)
|
2023-03-23 |
2025-11-14 |
广州百济神州生物制药有限公司 |
生物活性结合物、其制备方法和其用途
|
|
WO2024246657A1
(en)
*
|
2023-05-29 |
2024-12-05 |
Intas Pharmaceuticals Ltd. |
Method for conjugation and purification of antibody drug conjugate
|
|
EP4473974A1
(en)
|
2023-06-07 |
2024-12-11 |
Peptomyc, S.L. |
Omomyc and kras inhibitors combination therapy for the treatment of cancer
|
|
IL325025A
(en)
|
2023-06-07 |
2026-01-01 |
Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron |
Combination therapy with BRAF inhibitors for cancer treatment
|
|
IL324909A
(en)
|
2023-06-07 |
2026-01-01 |
Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron |
Combination therapy with mek inhibitors for the treatment of cancer
|
|
EP4725969A1
(en)
|
2023-06-09 |
2026-04-15 |
Latticon (Suzhou) Biopharmaceuticals Co., Ltd. |
Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
|
|
EP4737483A1
(en)
|
2023-06-30 |
2026-05-06 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate production method including purification step using activated carbon material
|
|
US12319747B2
(en)
|
2023-07-03 |
2025-06-03 |
Medicovestor, Inc. |
Methods of using anti-SP17 immunotherapeutics
|
|
WO2025019790A1
(en)
|
2023-07-19 |
2025-01-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
US12364777B2
(en)
|
2023-10-20 |
2025-07-22 |
Medicovestor, Inc. |
Homodimeric antibodies for use in treating cancers and methods of use
|
|
WO2025094146A1
(en)
|
2023-11-02 |
2025-05-08 |
Immunogen Switzerland Gmbh |
Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
|
|
US12116410B1
(en)
|
2023-12-26 |
2024-10-15 |
Medicovestor, Inc. |
Methods of manufacturing dimeric antibodies
|
|
US12600795B2
(en)
|
2023-12-26 |
2026-04-14 |
Medicovestor, Inc. |
Oligomeric IgG for immunotherapeutics and diagnostics
|
|
US12258396B1
(en)
|
2024-02-02 |
2025-03-25 |
Medicovestor, Inc. |
Methods of using immunotherapeutics that bind folate receptor alpha
|
|
US12240900B1
(en)
|
2024-02-02 |
2025-03-04 |
Medicovestor, Inc. |
Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
|
|
US12378314B1
(en)
|
2024-02-02 |
2025-08-05 |
Medicovestor, Inc. |
Proteins that bind folate receptor alpha including fully-human antibodies
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025223455A1
(en)
|
2024-04-24 |
2025-10-30 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Anti-ptk7/b7h3 antibodies and uses thereof
|
|
US20260048137A1
(en)
|
2024-08-16 |
2026-02-19 |
Ardeagen Corporation |
Anti-mesothelin antibody conjugates and methods of use thereof
|
|
WO2026057740A1
(en)
|
2024-09-12 |
2026-03-19 |
Astrazeneca Ab |
Treatment of cancer with therapeutic binding molecules
|
